The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant
Open accessAbstract
IMPORTANCE: Several factors are associated with increased hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT), but no reliable risk score has been established to determine the individual risk for HCC recurrence. OBJECTIVE: We aimed to develop and validate a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) score for patients with HCC meeting Milan criteria by imaging. DESIGN, SETTING, AND PARTICIPANTS: Predictors of recurrence were tested in a development cohort of 721 patients who underwent LT between 2002 and 2012 at 3 academic transplant centers (University of California-San Francisco; Mayo Clinic, Rochester; and Mayo Clinic, Jacksonville) to create the RETREAT score. This was subsequently validated in a cohort of 341 patients also meeting Milan criteria by imaging who underwent LT at the University of Toronto transplant center using the C concordance statistic and net reclassification index. MAIN OUTCOMES AND MEASURES: Characteristics associated with post-LT HCC recurrence. RESULTS: A total of 1061 patients participated in the study; 77.8% (825) were men, and the median (IQR) age was 58.2 (53.3-63.9) years in the development cohort and 56.4 (51.7-61.0) years in the validation cohort (P < .001). In the development cohort of 721 patients (542 men), median α-fetoprotein (AFP) level at the time of LT was 8.3 ng/mL; 9.4% had microvascular invasion (n = 68), and 22.1% were beyond Milan criteria on explant (n = 159) owing to understaging by pretransplantation imaging. Cumulative probabilities of HCC recurrence at 1 and 5 years were 5.7% and 12.8%, respectively. On multivariable Cox proportional hazards regression, 3 variables were independently associated with HCC recurrence: microvascular invasion, AFP at time of LT, and the sum of the largest viable tumor diameter and number of viable tumors on explant. The RETREAT score was created using these 3 variables, with scores ranging from 0 to 5 or higher that were highly predictive of HCC recurrence (C statistic, 0.77). RETREAT was able to stratify 5-year post-LT recurrence risk ranging from less than 3% with a score of 0 to greater than 75% with a score of 5 or higher. The validation cohort (n = 340; 283 men) had significantly higher microvascular invasion (23.8% [n = 81], P < .001), explant beyond Milan criteria (37.3% [n = 159], P < .001), and HCC recurrence at 5 years (17.9% [n = 159], P = .03). RETREAT showed good model discrimination (C statistic, 0.82; 95% CI, 0.77-0.86) and superior recurrence risk classification compared with explant Milan criteria (net reclassification index, 0.40; P = .001) in the validation cohort. CONCLUSIONS AND RELEVANCE: We have developed and validated a simple and novel prognostic score that may improve post-LT HCC surveillance strategies and help identify patients who may benefit from future adjuvant therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Presentation of multivariate data for clinical use: The Framingham Study risk score functions
Sullivan, L. M., Massaro, J. M., & D'Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1742 · Cited by 1,753
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Clavien, P.-A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,026
Duvoux, C., Roudot–Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T., Francoz, C., Compagnon, P., Vanlemmens, C., Dumortier, J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.052 · Cited by 955
Yao, F. Y., Xiao, L., Bass, N. M., Kerlan, R., Ascher, N. L., & Roberts, J. P. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01965.x · Cited by 562
Self-citationYao, F. Y., Mehta, N., Flemming, J., Dodge, J., Hameed, B., Fix, O., Hirose, R., Fidelman, N., Kerlan, R. K., & Roberts, J. P. (2015) · Hepatology · doi:10.1002/hep.27752 · Cited by 485
Self-citationGeissler, E. K., Schnitzbauer, A. A., Zülke, C., Lamby, P. E., Proneth, A., Duvoux, C., Burra, P., Jauch, K.-W., Rentsch, M., Ganten, T. M., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000000965 · Cited by 433
Pomfret, E. A., Washburn, K., Wald, C., Nalesnik, M. A., Douglas, D., Russo, M., Roberts, J., Reich, D. J., Schwartz, M. E., Mieles, L., et al. (2010) · Liver Transplantation · doi:10.1002/lt.21999 · Cited by 393
Self-citationToso, C., Merani, S., Bigam, D. L., Shapiro, A. M. J., & Kneteman, N. M. (2010) · Hepatology · doi:10.1002/hep.23437 · Cited by 329
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
Hameed, B., Mehta, N., Sapisochin, G., Roberts, J. P., & Yao, F. Y. (2014) · Liver Transplantation · doi:10.1002/lt.23904 · Cited by 279
Self-citationZimmerman, M. A. (2008) · Archives of Surgery · doi:10.1001/archsurg.2007.39 · Cited by 278
Rodríguez-Perálvarez, M., Tsochatzis, E., Naveas, M. C., Pieri, G., García-Caparrós, C., O’Beirne, J., Poyato-González, A., Ferrín-Sánchez, G., Montero-Álvarez, J. L., Patch, D., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.012 · Cited by 264
Agopian, V. G., Harlander-Locke, M., Zarrinpar, A., Kaldas, F. M., Farmer, D. G., Yersiz, H., Finn, R. S., Tong, M., Hiatt, J. R., & Busuttil, R. W. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.12.025 · Cited by 252
Vivarelli, M., Cucchetti, A., Barba, G. L., Ravaioli, M., Del Gaudio, M., Lauro, A., Grazi, G. L., & Pinna, A. D. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e3181896278 · Cited by 236
Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma
Zimmerman, M. A., Trotter, J. F., Wachs, M., Bak, T., Campsen, J., Skibba, A., & Kam, I. (2008) · Liver Transplantation · doi:10.1002/lt.21420 · Cited by 206
Lai, Q., Avolio, A. W., Graziadei, I., Otto, G., Rossi, M., Tisone, G., Goffette, P., Vogel, W., Pitton, M. B., & Lerut, J. (2013) · Liver Transplantation · doi:10.1002/lt.23706 · Cited by 201
Xu, J., Shen, Z.-Y., Chen, X.-G., Zhang, Q., Bian, H.-J., Zhu, P., Xu, H.-Y., Song, F., Yang, X.-M., Mi, L., et al. (2007) · Hepatology · doi:10.1002/hep.21465 · Cited by 183
Sapisochin, G., Goldaracena, N., Astete, S., Laurence, J. M., Davidson, D., Rafael, E., Castells, L., Sandroussi, C., Bilbao, I., Dopazo, C., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4273-6 · Cited by 181
Self-citationCholongitas, E., Mamou, C., Rodríguez-Castro, K. I., & Burra, P. (2014) · Transplant International · doi:10.1111/tri.12372 · Cited by 179
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADRESS‐HCC risk model
Flemming, J. A., Yang, J. D., Vittinghoff, E., Kim, W. R., & Terrault, N. A. (2014) · Cancer · doi:10.1002/cncr.28832 · Cited by 178
Berry, K., & Ioannou, G. N. (2013) · Liver Transplantation · doi:10.1002/lt.23652 · Cited by 171
Impact of Sirolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation
Chinnakotla, S., Davis, G. L., Vasani, S., Kim, P., Tomiyama, K., Sanchez, E. Q., Onaca, N. N., Goldstein, R. M., Levy, M. F., & Klintmalm, G. B. (2009) · Liver Transplantation · doi:10.1002/lt.21953 · Cited by 151
Agopian, V. G., Morshedi, M. M., McWilliams, J. P., Harlander‐Locke, M. P., Markovic, D., Zarrinpar, A., Kaldas, F. M., Farmer, D. G., Yersiz, H., Hiatt, J. R., et al. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000001384 · Cited by 151
Halazun, K. J., Patzer, R. E., Rana, A. A., Verna, E. C., Griesemer, A., Parsons, R. F., Samstein, B., Guarrera, J. V., Kato, T., Brown, R. S., et al. (2014) · Hepatology · doi:10.1002/hep.27272 · Cited by 134
Chaiteerakij, R., Zhang, X., Addissie, B. D., Mohamed, E. A., Harmsen, W. S., Theobald, P. J., Peters, B. E., Balsanek, J. G., Ward, M. M., Giama, N. H., et al. (2015) · Liver Transplantation · doi:10.1002/lt.24117 · Cited by 124
Self-citationHakeem, A. R., Young, R. S., Marangoni, G., Lodge, J. P. A., & Prasad, R. K. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05060.x · Cited by 116
Kim, D. J., Clark, P. J., Heimbach, J. K., Rosen, C. B. B., Sánchez, W., Watt, K. D. S., & Charlton, M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12684 · Cited by 101
Self-citationSchlansky, B. L., Chen, Y., Scott, D. L., Austin, D. F., & Naugler, W. E. (2014) · Liver Transplantation · doi:10.1002/lt.23917 · Cited by 91
Samoylova, M. L., Dodge, J. L., Yao, F. Y., et al. (2014) · Liver Transplantation · doi:10.1002/lt.23902 · Cited by 83
Self-citationmTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux, C., & Toso, C. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.02.003 · Cited by 82
Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era
Levi, D., Tzakis, A. G., Martin, P. B., et al. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2010.01.007 · Cited by 45
Ferreiro, A. O., Vázquez-Millan, M. Á., López, F. S., Gutiérrez, M. G., Pértega-Díaz, S., & Patiño, M. J. L. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.08.045 · Cited by 40
Mehta, N. J., & Yao, F. Y. (2013) · Liver Transplantation · doi:10.1002/lt.23730 · Cited by 39
Self-citationSiegel, A. B., El-Khoueiry, A. B., Finn, R. S., Guthrie, K. A., Goyal, A., Venook, A. P., Blanke, C. D., Verna, E. C., Dove, L. M., Emond, J. C., et al. (2015) · Liver Cancer · doi:10.1159/000367734 · Cited by 30
Montalti, R., Mimmo, A., Rompianesi, G., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182a8607e · Cited by 27
Chen, K., Man, K., Metselaar, H. J., Janssen, H. L. A., Peppelenbosch, M. P., & Pan, Q. (2013) · Liver Transplantation · doi:10.1002/lt.23806 · Cited by 26
Lundberg, J., Stone-Elander, S., Zhang, X.-M., Korsgren, O., Jonsson, S., & Holmin, S. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12601 · Cited by 15
Cited by
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Self-citationAASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“[245,246] Both the Metroticket 2.0 [247] and French AFP models [248] demonstrated that a combination of AFP and tumor burden predicts post-LT outcome better than tumor burden alone.”
InfluentialSelf-citationPrognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma
Erstad, D. J., & Tanabe, K. K. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07227-9 · Cited by 428
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Ahn, J. C., Teng, P., Chen, P., Posadas, E., Tseng, H., Lu, S. C., & Yang, J. D. (2021) · Hepatology · doi:10.1002/hep.31165 · Cited by 338
Metadata
- Authors
- Mehta, N., Heimbach, J., Harnois, D. M., Sapisochin, G., Dodge, J. L., Lee, D., Burns, J. M., Sanchez, W., Greig, P. D., Grant, D. R., Roberts, J. P., & Yao, F. Y.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-04-01
- Volume
- 3
- Issue
- 4
- Pages
- 493
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2553293686
- Cited by
- 398
- References
- 43
- FWCI
- 13.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.